Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A pilot study
Autore:
Denton, CP; Howell, K; Stratton, RJ; Black, CM;
Indirizzi:
Royal Free & Univ Coll Sch Med, Ctr Rheumatol, London NW3 2PF, England Royal Free & Univ Coll Sch Med London England NW3 2PF n NW3 2PF, England
Titolo Testata:
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
fascicolo: 4, volume: 18, anno: 2000,
pagine: 499 - 502
SICI:
0392-856X(200007/08)18:4<499:LLMWHT>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
SYSTEMIC-SCLEROSIS; PHENOMENON SECONDARY;
Keywords:
scleroderma; laser Doppler flowmetry; clinical trial; anticoagulant;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Black, CM Royal Free & Univ Coll Sch Med, Ctr Rheumatol, Royal Free Campus,Rowland Hill St, London NW3 2PF, England Royal Free & Univ Coll Sch Med Royal Free Campus,Rowland Hill St London England NW3 2PF
Citazione:
C.P. Denton et al., "Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: A pilot study", CLIN EXP RH, 18(4), 2000, pp. 499-502

Abstract

ObjectiveTo investigate tolerability and efficacy of low molecular weight (LMW) heparin therapy in patients with severe Raynaud's phenomenon. MethodsA prospective parallel group study comparing patients receiving regular subcutaneous LMW heparin (n = 16) with a matched control group (n = 14). End-points were change in Raynaud's attack severity, non-invasive vascular studies or serum levels of circulating soluble adhesion molecules. ResultsThere was overall improvement in Raynaud's attack severity during heparin therapy (p = 0.0002). This was observed after 4 weeks, and was maximal by 20 weeks. Mean finger blood flow recovery time improved, and serum levels ofcirculating ICAM-1, VCAM-1 and E-selectin were lower at completion of heparin therapy, but changes did not reach statistical significance. ConclusionThis study suggests that LMW heparin therapy is well tolerated, and potentially beneficial, in patients with severe Raynaud's phenomenon, and justifies further evaluation.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 14/07/20 alle ore 18:34:27